SAREPTA THERAPEUTICS, INC. Gain (Loss) on Sale of Properties
SAREPTA THERAPEUTICS, INC. (SRPT) reported Gain (Loss) on Sale of Properties of -$200.00 thousand for the 3-month period ending 2017-09-30, per its 10-Q filed 2017-11-01.
Discontinued › Cash Flow › Operating Activities
us-gaap:GainLossOnSaleOfProperties · last filed 2017-11-01
- SAREPTA THERAPEUTICS, INC. gain (loss) on sale of properties for the quarter ending 2017-09-30 was -$200.00K.
| Period end | Gain (Loss) on Sale of Properties 3 month | Gain (Loss) on Sale of Properties 9 month |
|---|---|---|
| 2017-09-30 | -$200.00K 10-Q · filed 2017-11-01 | -$200.00K 10-Q · filed 2017-11-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |